ClinicalTrials.gg
WithdrawnNCT05953831REMOD-REVERTUpdated Jul 7, 2026

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

A Phase 2 interventional study of CDR132L and Placebo in Heart Failure With Preserved Ejection Fraction, sponsored by Cardior Pharmaceuticals GmbH. Withdrawn. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Cardior Pharmaceuticals GmbH (part of Novo Nordisk A/S) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Transfer of study responsibility and planning

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Heart Failure by Novo Nordisk A/S — 5 open to participants now, 6 under way, 2 of them phase 3. Heart Failure · Novo Nordisk A/S.

Enrollment
11th of 11
0 · median 200
Started
2024
with 2 others
Phase 2
4 of 14
2 open now
Registered
4th of 14
by date

Among the 14 studies in Heart Failure by Novo Nordisk A/S, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 4th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 14 studies in Heart Failure by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Failure by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess efficacy and safety of CDR132L on reverse remodeling. In this study, patients with HFpEF (EF ≥50%) or HFmrEF (LVEF 45-49%) will be included.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Keywords

  • HFpEF
  • Heart failure
  • Cardiac Hypertrophy
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Provision of signed prior to any study-specific procedures.
  2. Male or female of non- patients age ≥40 and \<85 years.
  3. Documented diagnosis of symptomatic heart failure ( class II-IV) at enrollment, and a medical history of typical symptoms/signs of heart failure ≥6 weeks before enrollment with at least intermittent need for diuretic treatment.
  4. ≥45% (determined by echocardiography at site laboratory)
  5. Increased intraventricular wall thickness (≥11 mm for female and ≥12 mm for male patients by echocardiography at site laboratory)
  6. NT-proBNP > 300 pg/ml (sinus rhythm); >900 pg/ml (atrial fibrillation at time of screening/inclusion or documented with the last 6 months)
  7. between 22 kg/m² and 45 kg/m².

Main Exclusion Criteria:

  1. (A1C) ≥10.5%
  2. \<35 mL/min/1.73m²
  3. Systolic blood pressure (BP) \<90 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening.
  4. Systolic BP≥180 mmHg on 2 consecutive measurements at 5-minute intervals, at Screening.
  5. Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement.
  6. Stroke or (TIA) within 12 weeks prior to enrolment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CDR132L 4.52 mg

    Six times CDR132L 4.52 mg/kg body weight intravenous in single dose.

    Drug: CDR132L

  • Placebo comparator
    Placebo

    Six times Placebo intravenous in single dose.

    Drug: Placebo

Interventions

  • CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.

  • DrugPlacebo

    Placebo to CDR132L

06

What researchers measure

Primary outcomes

  1. Left ventricular mass

    Left ventricular mass measured by cardiac magnetic resonance imaging (indexed to the height in meters raised to the power of 2)

    Time frame: 6 months

  2. Left atrial maximum volume

    Left atrial maximum volume (measured by cardiac magnetic resonance imaging in end systole(indexed to the height in meters raised to the power of 2))

    Time frame: 6 months

  3. Total cardiac extracellular volume

    Total cardiac extracellular volume (mL) measured by cardiac magnetic resonance imaging

    Time frame: 6 months

  4. Left atrial strain

    Left atrial strain measured by cardiac magnetic resonance imaging

    Time frame: 6 months

  5. Maximum left ventricular wall thickness

    Maximum left ventricular wall thickness measured by cardiac magnetic resonance imaging

    Time frame: 6 months

  6. Age-adjusted e' velocity

    Age-adjusted e' velocity measured by doppler echocardiography. With e´velocity being the maximal velocity of mitral annular motion (E-wave).

    Time frame: 6 months

  7. Global longitudinal strain

    Global longitudinal strain measured by echocardiography

    Time frame: 6 months

  8. E/e'

    E/e' measured by doppler echocardiography to evaluate the LV filling pressure.

    Time frame: 6 months

  9. Concentration of N-terminal pro B-type natriuretic peptide

    Concentration measured as biomarker from blood samples.

    Time frame: 6 months

  10. Concentration of high-sensitivity cardiac troponin T

    Concentration measured as biomarker from blood samples.

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2024; primary completion for Sep 2025, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 20, 2023
StartEst.
Apr 30, 2024
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2025
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953831
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Apr 30, 2024 (estimated)
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jul 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDR132L

Start the discussion